1 Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology. 2017;65: 2100-9.
2 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52: 1836-46.
3 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142: 1592-609.
4 Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65: 1557-65.
5 Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score, and APRI for NAFLD-related events: a systematic review. Liver Int. 2020.
6 European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64: 1388-402.
7 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol. 2021;18: 73-91.
8 Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human non-alcoholic fatty liver disease. Hepatology. 2013.
9 Khoury T, Mari A, Nseir W, Kadah A, Sbeit W, Mahamid M. Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2019;31: 1110-5.
10 Wada N, Takaki A, Ikeda F, et al. Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease. Hepatol Int. 2017;11: 115-24.
11 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116: 1413-9.
12 Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2009;7: 1104-12.
13 Kruger FC, Daniels CR, Kidd M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2011;101: 477-80.
14 Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67: 1265-73.
15 McPherson S, Hardy T, Dufour JF, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. The American journal of gastroenterology. 2017;112: 740-51.
16 Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol. 2021.
17 Breitkopf K, Roeyen C, Sawitza I, Wickert L, Floege J, Gressner AM. Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine. 2005;31: 349-57.
18 Ikura Y, Morimoto H, Ogami M, Jomura H, Ikeoka N, Sakurai M. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. Journal of gastroenterology. 1997;32: 496-501.
19 Kurys-Denis E, Prystupa A, Luchowska-Kocot D, Krupski W, Bis-Wencel H, Panasiuk L. PDGF-BB homodimer serum level - a good indicator of the severity of alcoholic liver cirrhosis. Ann Agric Environ Med. 2020;27: 80-5.
20 Zhou J, Deng Y, Yan L, Zhao H, Wang G, China Hep BRFARG. Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B. Int J Infect Dis. 2016;49: 94-9.
21 Anatol P, Robert F, Danuta P. Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C. World J Gastroenterol. 2005;11: 1854-8.
22 Yoshida S, Ikenaga N, Liu SB, et al. Extrahepatic platelet-derived growth factor-beta, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147: 1378-92.
23 Li M, Sun X, Zhao J, et al. CCL5 deficiency promotes liver repair by improving inflammation resolution and liver regeneration through M2 macrophage polarization. Cell Mol Immunol. 2020;17: 753-64.
24 Hu L, Zhu Y, Zhang J, et al. Potential circulating biomarkers of circulating chemokines CCL5, MIP-1beta and HA as for early detection of cirrhosis related to chronic HBV (hepatitis B virus) infection. BMC Infect Dis. 2019;19: 523.